Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

PD-1 Data Promise More Shake-ups In Melanoma Standard of Care

Apr 20 2015

• By Emily Hayes

Related Content

Yervoy Cuts To The Head Of The Line: Ipilimumab Has Unrestricted Label

Mar 28 2011

Yervoy/Nivolumab May Need Stronger Survival Data To Be First Choice In Melanoma

Jun 02 2014

Related Companies

Merck & Co., Inc.

Bristol Myers Squibb Company

Additional Topics

Clinical Trials BioPharmaceutical

More from Clinical Trials

More from R&D

Twitter feed RSS feed RSS feed

About UsOpens in new window
Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us
Customer Service
Subscribe
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window